#Blueprint medicine stock price free

Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. In November 2021, the European Commission approved Qinlock for the same indication.ĭeciphera is looking to streamline commercial operations for Qinlock in the United States and focus on commercialization efforts on a select number of key European markets for the medicine.

#Blueprint medicine stock price free

Hence, any regulatory setback for the drug could hurt the stock in the days ahead.Īlso, Ayvakit faces competition from Deciphera Pharmaceuticals' ( DCPH Quick Quote DCPH - Free Report) Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. LNG-451, a potential best-in-class oral precision therapy, is currently being developed for the treatment of non-small cell lung cancer in patients with EGFR exon 20 insertion mutations.īlueprint Medicines’ current product revenues solely comprise sales from Ayvakit, which narrows its revenues stream. The acquisition added Lengo Therapeutics’ lead compound, LNG-451, to Blueprint Medicines’ portfolio. The acquisition will expand Blueprint Medicines’ precision oncology therapies and transform treatment for patients with EGFR-driven lung cancer. In December 2021, Blueprint Medicines closed the previously announced acquisition of privately held biopharmaceutical company, Lengo Therapeutics. This apart, Blueprint Medicines has other promising pipeline candidates that are progressing well, targeting various cancer indications. Gavreto is also approved for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer. The FDA approved Gavreto for treating advanced/metastatic RET-mutant and RET fusion-positive thyroid cancer, in December 2020. The company only records the share of profit and loss for Gavreto in financial results and does not record any net product revenues from Gavreto sales. In July 2021, Blueprint Medicines transferred the responsibilities of booking U.S. Ayvakit is being evaluated in the phase II PIONEER study for treating non-advanced SM.īlueprint Medicines is co-developing another cancer drug, Gavreto (pralsetinib), with Roche ( RHHBY Quick Quote RHHBY - Free Report) for treating patients with various types of RET-altered thyroid cancers and other solid tumors.

In June 2021, the FDA approved Ayvakit for a new indication – advanced systemic mastocytosis (“SM”), a rare and debilitating disease.

The European Commission has granted conditional marketing authorization to Ayvakyt as a monotherapy for the treatment of adult patients with unresectable/metastatic GIST, harboring the PDGFRA D842V mutation.Īyvakit/Ayvakyt has witnessed strong uptake since its launch. The company has made steady progress with its lead drug, Ayvakit (avapritinib), approved by the FDA for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, in this time frame. Shares of Blueprint Medicines Corporation ( BPMC Quick Quote BPMC - Free Report) have rallied 24.8% in the past six months against the industry’s decrease of 18.7%.